The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | 21,567 | -28,235 |
| Depreciation and amortization | 4,029 | 7,178 |
| Amortization of intangible assets | 842 | 1,683 |
| Reduction in the carrying value of right-of-use assets | 2,116 | 4,077 |
| Non-cash interest expense | 69 | 139 |
| Deferred tax benefit | -3,837 | -2,292 |
| Provision recorded for credit losses | 2,287 | 3,116 |
| Loss on disposal of property and equipment | -29 | -44 |
| Adjustment for excess and obsolete inventories | -1,870 | -6,093 |
| Stock-based compensation | 3,065 | 5,909 |
| Write-down to fair value for asset held for sale (note 6) | 922 | 8,313 |
| Accounts receivable | 50,688 | 13,637 |
| Inventories | -938 | 15,892 |
| Prepaid expenses and other current assets and other assets | -9,644 | 12,942 |
| Operating leases | 2,155 | 4,147 |
| Accounts payable | -994 | 1,637 |
| Accrued expenses and other current liabilities | 11,943 | -13,886 |
| Other liabilities | 1,432 | 34 |
| Net cash provided by (used in) operating activities | 3,079 | -52,808 |
| Purchases of property and equipment | 2,235 | 7,264 |
| Net cash used in investing activities | -2,235 | -7,264 |
| Landlord assets under construction, net of tenant allowance | 10,039 | - |
| Payments of withholding taxes in connection with rsus vesting | 2 | 1,796 |
| Proceeds from the exercise of stock options | 130 | 25 |
| Principal repayments of finance lease obligations | 296 | 573 |
| Net cash used in financing activities | -10,207 | -2,344 |
| Change in cash, cash equivalents and restricted cash | -9,363 | -62,416 |
| Cash and cash equivalents at beginning of period | 136,151 | - |
| Cash and cash equivalents at end of period | 64,372 | - |
Organogenesis Holdings Inc. (ORGO)
Organogenesis Holdings Inc. (ORGO)